Calcium Channel Blockers and Cardiac Potassium Currents
Yes, certain calcium channel blockers do inhibit IKr (hERG) and IKs, though the degree of inhibition varies significantly by agent. Specifically, bepridil, verapamil, and mibefradil block IKr, while bepridil and mibefradil also inhibit IKs; in contrast, nitrendipine and diltiazem have negligible effects on these potassium currents 1.
Specific CCB Effects on Potassium Channels
IKr (hERG) Inhibition
The research evidence demonstrates clear differential effects:
- Bepridil: Most potent IKr blocker (EC50 = 0.55 μM) 1
- Verapamil: Moderate IKr inhibition (EC50 = 0.83 μM) 1
- Mibefradil: Weaker IKr inhibition (EC50 = 1.43 μM) 1
- Diltiazem and nitrendipine: Negligible IKr effects 1
These blockers also shift steady-state activation and inactivation parameters to more negative values, which can prolong repolarization 1.
IKs (KvLQT1-IsK) Inhibition
The pattern differs for IKs:
- Bepridil: Inhibits IKs (EC50 = 10.0 μM) 1
- Mibefradil: Inhibits IKs (EC50 = 11.8 μM) 1
- Verapamil, diltiazem, and nitrendipine: No significant IKs inhibition 1
Clinical Implications
Arrhythmia Risk
The inhibition of IKr and IKs by certain CCBs explains several clinical observations:
- Verapamil's efficacy in ventricular tachycardias may relate to its IKr blocking properties 1
- Adverse cardiac events with bepridil and mibefradil are mechanistically linked to their dual inhibition of both IKr and IKs 1
- The class III antiarrhythmic potassium channel blockers d-sotalol and dronedarone should be avoided in heart failure patients due to increased mortality 2
Heart Failure Context
Calcium channel blockers should generally be avoided in patients with HFrEF 2, 3, 4, 2. The guidelines consistently recommend against routine CCB use in heart failure, with amlodipine being the only exception when needed for hypertension or ischemic heart disease management, as it had neutral mortality effects in large trials 2, 3, 4.
Practical Considerations
When prescribing CCBs, consider:
- Dihydropyridines (nifedipine, amlodipine, nitrendipine) have minimal potassium channel effects and primarily cause vasodilation
- Non-dihydropyridines (verapamil, diltiazem) have variable potassium channel effects, with verapamil showing significant IKr inhibition
- Bepridil and mibefradil carry the highest risk due to dual IKr/IKs inhibition and are associated with adverse cardiac events 1
The natural variability in ionic current profiles contributes to individual susceptibility to arrhythmias, and IKr serves as a protective current against action potential prolongation 5. This explains why some patients tolerate CCBs with potassium channel blocking properties while others develop arrhythmias.